Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia

Natasha Yap; Vanessa Wong; Catherine Morton; Richard de Boer; Sally Baron-Hay; Robert Blum; Benjamin Forster; Susan Chua; Kerrie Clarke; Katharine Cuff; Michael Green; Elgene Lim; Kelly Mok; Louise Nott; Michelle Nottage; Ali Tafreshi; Daphne Tsoi; Anthony Uccellini; Peter Gibbs; Sheau Wen Lok

doi:10.1111/imj.16536

Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia

Intern Med J. 2024 Nov;54(11):1894-1897. doi: 10.1111/imj.16536. Epub 2024 Oct 28.

Authors

Natasha Yap¹, Vanessa Wong^{2

3}, Catherine Morton², Richard de Boer^{4

5}, Sally Baron-Hay⁶, Robert Blum⁷, Benjamin Forster⁸, Susan Chua⁹, Kerrie Clarke¹⁰, Katharine Cuff¹¹, Michael Green¹², Elgene Lim¹³, Kelly Mok¹⁴, Louise Nott¹⁵, Michelle Nottage¹⁶, Ali Tafreshi¹⁷, Daphne Tsoi¹⁸, Anthony Uccellini¹⁹, Peter Gibbs^{2

3}, Sheau Wen Lok^{2

4}

Affiliations

¹ Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
² Gibbs Labs, Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
³ Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁵ St Vincent's Private Hospital, Melbourne, Victoria, Australia.
⁶ Department of Medical Oncology, Northern Cancer Institute, Sydney, New South Wales, Australia.
⁷ Department of Medical Oncology, Bendigo Health, Bendigo, Victoria, Australia.
⁸ Department of Medical Oncology, Mater Hospital, Sydney, New South Wales, Australia.
⁹ Department of Medical Oncology, Eastern Health, Melbourne, Victoria, Australia.
¹⁰ Department of Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia.
¹¹ Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
¹² Epworth Freemasons, Melbourne, Victoria, Australia.
¹³ Department of Medical Oncology, Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
¹⁴ Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁵ Department of Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
¹⁶ Department of Medical Oncology, Royal Brisbane Hospital, Brisbane, Queensland, Australia.
¹⁷ Department of Medical Oncology, Wollongong Private Hospital, Wollongong, New South Wales, Australia.
¹⁸ Department of Medical Oncology, St John of God Hospital, Perth, Western Australia, Australia.
¹⁹ Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.

PMID: 39467087
DOI: 10.1111/imj.16536

Abstract

This study evaluated patient-reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expressed gratitude for accessing non-funded medications and perceived enhanced medication adherence as a key benefit. Integrating PRO data with real-world registry data provides comprehensive insight for future MAP development.

Keywords: Medication Access Programme; patient‐reported outcome; quality of life.

MeSH terms

Adult
Aged
Aminopyridines* / therapeutic use
Antineoplastic Agents / therapeutic use
Australia
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Health Services Accessibility
Humans
Medication Adherence
Middle Aged
Neoplasm Metastasis
Patient Reported Outcome Measures*
Purines* / therapeutic use

Substances

ribociclib
Purines
Aminopyridines
Antineoplastic Agents